Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Development of Assays for Diagnostics, Biothreat Agents

by Global Biodefense Staff
November 21, 2014
Brevetoxin Antibody Research

The U.S. Army Medical Research and Materiel Command (USAMRMC) is looking to develop multiple immunochromatographic tests (ICTs) for the detection of infectious diseases and biological warfare agents (BWA).

USAMRMC has issued a pre-solicitation notice for a small business indefinite delivery indefinite quantity (ID/IQ) contract vehicle for potential activities including development of:

  • Rapid Human Diagnostic Devices (RHDDs) for military-relevant IDs, including: dengue fever and dengue hemorrhagic fever, bacterial gastroenteritis, viral gastroenteritis
  • Biological Warfare Agent (BWA) and related disease rapid diagnostics, such as brucellosis and western/eastern equine encephalitis viruses
  • Arthropod Vector Rapid Detection Devices (AVRDDs) for military-relevant vector-borne diseases including but not limited to dengue virus, Leishmania species, and Plasmodium species

The contractor is required to have manufacturing facilities in compliance with Current Good Manufacturing Practice (cGMP) and will be the sponsor for the 510(k) of each ICT assay for the FDA.

The period of performance (POP) for the ID/IQ contract will be five years in duration, with one 12 month base period, accompanied by 4 twelve month option periods. Each Task Order issued under the ID/IQ for this requirement will have the potential to have a 4 year POP, depending on the advancement/development of the assays required.

Further details are available under Solicitation Number: W81XWH-15-R-0014.

Tags: BrucellaDengueEquine EncephalitisLeishmaniasisMalariaRequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC